Biological
JNJ-64300535 clinical trials
Also written JNJ-64300535.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2018
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Janssen Research & Development, LLC (2) · Janssen Sciences Ireland UC (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses JNJ-64300535 is read from its arms, and is right about nine times in ten.
Testing it · 3
- A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBeAg)- Negative Participants With Chronic Hepatitis B Virus InfectionCompletedPhase 1Janssen Research & Development, LLCNCT05123599Written as JNJ-64300535
- A Study of JNJ-64300535 in Healthy ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT04736147Written as JNJ-64300535
- A First-In-Human Study to Evaluate Safety, Tolerability, Reactogenicity, and Immunogenicity of JNJ-64300535, a DNA Vaccine, Administered by Electroporation-Mediated Intramuscular Injection, in Participants With Chronic Hepatitis B Who Are on Stable Nucleos(t)Ide Therapy and Virologically SuppressedCompletedPhase 1Janssen Sciences Ireland UCNCT03463369Written as JNJ-64300535